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Atypical meningiomas have a greater propensity to recur than benign meningiomas and the benefits of early adjuvant radiotherapy are unclear. Existing studies report conflicting results.  This retrospective cohort study evaluated the role of early adjuvant radiotherapy following surgical resection of atypical meningioma.  A triple center case-note review of adults with newly-diagnosed atypical meningiomas between 2001-2010 was performed.  Pathology diagnosis was made according to the WHO classification in use at the time of surgery.  Patients with multiple meningiomas, Neurofibromatosis type 2 and radiation-induced meningiomas were excluded.  Extent of resection was defined as gross total resection (GTR: Simpson I-III) or subtotal resection (STR: Simpson IV-V).  Survival analysis was performed using the Kaplan-Meier method.  133 patients were identified with a median age of 62 years (range 22-86 years) and median follow-up of 57.4 months (range: 0.1-152.2 months).  Tumours were mostly located in the convexity (50.4%) or falcine / parasagittal regions (27.1%).  GTR (achieved in 85%) was associated with longer progression free survival (PFS) (5-year PFS 81.2% vs. 40.08%, log-rank=11.117, p=0.001) but not overall survival (OS) (5-year OS 76.6% vs. 39.7%, log-rank=3.652, p=0.056).  Following GTR, early adjuvant radiotherapy was administered to 28.3% of patients and did not influence OS (5-year OS 77.0% vs. 75.7%, log-rank=0.075, p=0.784) or PFS (5-year PFS 82.0 vs. 79.3%, log-rank=0.059, p=0.808).  Although extent of resection emerged as an important prognostic variable, early adjuvant radiotherapy did not influence outcome following gross total resection of atypical meningiomas. Prospective randomized controlled trials are planned.
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Meningiomas arise from the meningeal layers covering the brain and spinal cord and are the most common form of primary intracranial tumour [] with a prevalence of approximately 50.4 cases per 100,000  ADDIN EN.CITE [].  The latest version of the World Health Organization (WHO) classification of intracranial tumours defines three histological grades [], of which Grade II (atypical) meningiomas represent an intermediate grade that may account for up to 30-40% of all meningiomas  ADDIN EN.CITE [].  The 5-year recurrence rate is up to 40% in the absence of adjuvant radiotherapy  ADDIN EN.CITE [, ] and between 10-30% undergo malignant transformation to grade III tumours  ADDIN EN.CITE [, ].




The institutional review board at each participating center approved this study.  Eligibility criteria included (i) age ≥16 years; (ii) surgery performed between January 2001 and December 2010; (iii) histopathology diagnosis of grade II meningioma made according to the WHO classification in use at the time of diagnosis [, ].  Patients were excluded if they had multiple or recurrent meningiomas, neurofibromatosis type 2 or a history of previous cranial irradiation.

Clinical characteristics
Patient notes were reviewed to collect the following variables: age at surgery, clinical features, tumour location, surgical treatment, postoperative course and use of adjuvant radiotherapy (start date, dose and fractionation).  Extent of resection was assessed by Simpson grade, as recorded by the neurosurgeon in the operative notes (Table 1).  Post-operative MRI to confirmed extent of resection was not routinely performed in these patients.  Gross total resection (GTR) was defined as Simpson grades I-III, whilst subtotal resection (STR) was defined as Simpson grades IV-V (as endorsed by both the European Organization for Research and Treatment of Cancer (EORTC) and the Radiation Therapy Oncology Group (RTOG)).  Early adjuvant radiotherapy was defined as that received within 6 months of surgery.  Progression free survival (PFS) was calculated from the date of surgery to first radiological evidence of disease recurrence, or censored at the date of last follow-up in the absence of disease recurrence.  Overall survival (OS) was measured from the date of first surgery to the date of death (all-causes), or censored at the date of last follow-up if the patient was still alive.

INSERT TABLE 1 HERE

Statistical analysis





Between 2001-2010, 148 adult patients received a diagnosis of newly diagnosed WHO grade II meningioma.  Patients with multiple tumours (n=4), neurofibromatosis type 2 (n=3) and a history of prior cranial irradiation (n=5) were excluded from analysis. Two patients who received adjuvant radiotherapy 9-11 months postoperatively, and one patient who received adjuvant radiotherapy with palliative intent, were also excluded. The remaining 133 patients were included in this study (Table 2).  The median age at surgery was 62 years (range: 22-86) and the median follow-up was 57.4 months (range: 0.1-152.2).  No patient had neurofibromatosis type 1.





Clinical management is shown in figure 1.  Thirty-seven patients had operative complications and there were four deaths (3.0%).  Simpson grading was available in 132/133 patients.  113 patients (85.0%) underwent GTR and 19 patients (15.0%) underwent STR, including one patient who received a biopsy (grade V) for an intraventricular meningioma.  Patients who underwent STR tended to be older, although this differences was not statistically significant (median 61.0 vs. 69.5 years; Fisher’s Exact, p=0.082).  Extent of resection did not differ between skull base meningiomas and those in other locations (STR, 15.4% vs. 11.8%; Fisher’s Exact, p=0.739).

Early adjuvant radiotherapy
Thirty-six patients received fractionated external-beam radiotherapy. The median dose was 60 Gy in 30 fractions (range 54-60 Gy). The median time from surgery to the start of radiotherapy was 3.2 months (range: 0.9 – 7.2 months).  Two patients received radiotherapy at 9.6 and 10.9 months after surgery, due to postoperative complications, and with no evidence of tumour recurrence.  These patients were excluded from the ‘early radiotherapy’ group along with the patient who only received palliative 20Gy radiotherapy.  There was no significant difference between the proportion of patients receiving early adjuvant radiotherapy in the GTR and STR groups (28.3% vs. 21.1%; Fisher’s Exact, p=0.590).  Within the GTR group, there was no significant difference in age (median 58.5 vs. 62.0 years; Fisher’s Exact, p=0.402), gender (males 50.6% vs. 53.1%; Fisher’s Exact, p=0.837) or proportion of skull-base tumours (17.5% vs. 25.0%, Fisher’s Exact, p=0.432) between patients who received early adjuvant radiotherapy and those who did not.
In patients with subtotal resection (n = 19) early adjuvant radiotherapy was administered to 4 patients with tumours located mainly in the convexity/parasagittal-falcine area (n = 12, 63.2%) and skull-base (n = 6, 31.6%).

Recurrent tumour management
Recurrence occurred in 31 patients and only 11  were symptomatic - management varied considerably (Fig. 1).  Ten patients were managed with surveillance due to small and clinically unimportant regrowth.  17 patients underwent further surgery, of which 8 also received post-operative radiotherapy.  Stereotactic radiosurgery (marginal dose 12.5 Gy) was employed in 4 patients.  Only 10 patients had evidence of second recurrence.

Survival analysis
Univariate analysis using Kaplan-Meier survival curves and the log-rank test was used to evaluate the effect of variables on OS and PFS (Table 3 and Fig. 2).  The median OS for the entire cohort was not reached (Fig. 2A: range 0.1 - 152.2 months) and the 3-year and 5-year actuarial rates of OS were 84.4% (95% CI 78.1 - 90.7%) and 71.4% (95% CI 63.2 - 79.6), respectively.  The median PFS was not reached (range 0.1 - 152.2 months) and the 3-year and 5-year actuarial rates of PFS were 82.3% (95% CI 75.4 - 89.2%) and 74.7% (95% CI 66.5 - 82.9%), respectively.  Age had a significant effect on OS (5-year OS 84.4% vs. 57.1%, log-rank = 19.730, p<0.001) but not PFS (5-year PFS 80.2% vs. 67.3%, log-rank = 2.740, p = 0.098).  There were no survival differences according to tumour location or gender.  GTR was associated with better PFS (5-year PFS 40.0% vs. 81.2%, log-rank = 11.117, p = 0.001) (Fig. 2D) but not OS (5-year OS 39.7% vs. 76.6%, log-rank = 3.652, p=0.056).  Early adjuvant radiotherapy did not influence OS or PFS in the GTR group (Fig. 2C-D).
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DISCUSSION
Atypical meningiomas have a greater propensity to recur than benign meningiomas and the reported 5-year progression free survival rates ranges from 39-58%  ADDIN EN.CITE [, , , ] and the role of early adjuvant radiotherapy is not well defined.  This is one of the largest studies to report clinical outcomes in patients diagnosed using the latest histological criteria [, ].  Only newly-diagnosed, solitary meningiomas were included to produce a more uniform clinical cohort.  GTR (Simpson I-III) was achieved in 115 patients and was associated with prolonged PFS but not OS.  The addition of early adjuvant radiotherapy after GTR did not influence PFS or OS.

Extent of resection
Extent of resection has long been known to influence the likelihood of recurrence in meningiomas.  The Simpson grade is the established system, although some have recently challenged its prognostic value in the modern neurosurgical era.  In WHO grade I meningioma, Sughrue et al. found no statistically significant difference in tumour recurrence rates according to Simpson grade, though gross figures suggest otherwise (5-year PFS 95% vs. 81% for grades I and IV, respectively)  ADDIN EN.CITE [].  Indeed, grouping together Simpson grades into categories of GTR (grades I-III) and STR results in better prognostic value  ADDIN EN.CITE [] and these definitions have been adopted by the EORTC and RTOG.  In our study, patients who underwent GTR had a longer PFS, but this did not translate into longer OS, in concordance with other atypical meningiomas studies  ADDIN EN.CITE [, , ].  In contrast to our study, longer OS following GTR of atypical meningiomas has been reported  ADDIN EN.CITE [, ] and the absence of this finding in our study may reflect unequal groups size, such that the majority of our cases had complete resection.  The definition of GTR and STR also varies, indeed GTR has been variously defined as Simpson I  ADDIN EN.CITE [, ], Simpson I and II  ADDIN EN.CITE [] or Simpson I-III  ADDIN EN.CITE [, , ].  In a recent review paper GTR was described as Simpson I-III [] and most prospective clinical trials for meningioma adopt this definition.

Early adjuvant radiotherapy 
The use of early adjuvant radiotherapy after resection of atypical meningiomas is subject to major inter-institutional differences in practice  ADDIN EN.CITE [, ].  Neurosurgeons may be reluctant to refer patients for radiotherapy due to concerns about side effects, including neuro-cognitive deficits, however, two recent studies have found no significant difference in cognitive measures between irradiated and non-irradiated meningioma patients  ADDIN EN.CITE [, ].  Indeed, long-term follow-up of irradiated meningioma patients suggest few deleterious effects, although they can be severe on occasions, ranging from motor or sensory deficits to radiation induced tumours  ADDIN EN.CITE [].
In our study, regardless of the extent of resection, early adjuvant radiotherapy did not influence PFS or OS.  Whilst patient characteristics such as age and tumour location were similar between irradiated and non-irradiated patients providing a good control group, the number of patients in each group was not equal and these results should therefore be interpreted with caution.  The decision to treat with radiotherapy was based upon clinician and patient preference.  It is therefore likely that clinician bias was present in referring certain patients for radiotherapy.  Several other contemporary studies of atypical meningiomas have also found no survival benefit of early adjuvant radiotherapy, although all are retrospective with unequal patients groups  ADDIN EN.CITE [, , , , , ].
In contrast to our study, a multi-institutional French study reported on 166 patients with atypical meningiomas and demonstrated radiotherapy at any time point (early adjuvant or first recurrence) had longer PFS (35.2 vs. 65.7 months, p = 0.0006), although there was no improvement in OS  ADDIN EN.CITE [].  Other studies have reported similar improvement in local control but not overall survival  ADDIN EN.CITE [].
In all of these retrospective studies  ADDIN EN.CITE [, , ] the radiotherapy dose varies and there is no objective quality assurance assessment.  Indeed, even in controlled prospective studies there can be variation despite rigorous quality assurance measures [].  It is therefore possible that variation in treatment dose and plans contributed to poor local control in the irradiated patients.  There are two ongoing radiotherapy dose-escalation phase II studies and a phase III randomized controlled trial (RCT) in set-up, for atypical meningioma.  The EORTC 22042-26042 stratified patients to either 60 Gray for Simpson I-III resection, or 60 Gray + 10 Gray boost for Simpson IV-V resection.  In the US, the RTOG 0539 study for intermediate risk (group II: atypical meningioma, GTR) meningioma patients is also testing a dose escalation regime.  Both trials are closed to recruitment and whilst the results are eagerly anticipated, neither will study answer the question of whether radiotherapy is better than observation following gross total resection of atypical meningioma.  The ROAM/EORTC 1308 trial [ISRCTN71502099] (Radiation versus Observation following surgical resection of Atypical Meningioma) is a multi-center, phase III, RCT that will answer the question ‘in patients who have undergone gross total resection of atypical meningioma, does early adjuvant radiotherapy reduce recurrence compared to active monitoring?’[]  An award of £1.37 million has been made by the National Institute of Health Research Health Technology Assessment Program (NIHR-HTA) to fund this trial, with additional funding from Europe.  The trial is scheduled to open in 2015.

Study limitations
This was a retrospective design, with unequal patient groups, and an assumption that treatment differences were based on surgeon / patient preference rather than clinical equipoise.  In addition, we did not have data on the cause of death for all patients and it is possible that due to the unequal size of each group, there would be differences in the demographics and pre-existing co-morbidities that may have influenced overall survival.  However, for progression free survival all deaths were censored and the cause of death would not have affected this data.
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Kaplan-Meier survival curves. (A) The median OS for the entire cohort was not reached (0.1 - 152.2 months).   (B) Extent of resection was a significant predictor of PFS (5-year PFS 40.0% vs. 81.2%; log-rank=11.117, p=0.001).  After GTR, early adjuvant radiotherapy was not associated with: (C) improved PFS (5-year PFS 82.0% vs. 79.3%; log-rank = 0.059, p=0.808); or (D) OS (5-year OS 77.0% vs. 75.7%, log-rank = 0.075, p=0.784).
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